

# BIOPHARMICA LIMITED

Bridging Biotechnology Borders

Level 2, 30 Hasler Road,  
Osborne Park, Western Australia 6017

PO Box 1534,  
Osborne Park, Western Australia 6916

Telephone + 61 (08) 9244 9631

Facsimile + 61 (08) 9244 9782

Email [admin@biopharmica.com.au](mailto:admin@biopharmica.com.au)

Internet [www.biopharmica.com.au](http://www.biopharmica.com.au)

Press Release  
31st January 2005

Stock Code - BPH

ACN 095 912 002

## Cancer Expert Joins BioPharmica HLS5 Research Team

BioPharmica is pleased to confirm the appointment of Dr Jean-Philippe Lalonde to the HLS5 Cancer research team.

The move coincides with the appointment of further research staff to match the recent expansion in activity on the HLS5 project. BioPharmica has also agreed to an accelerated funding program in response to the research team's progress.

A review of studies conducted in the Laboratory for Cancer Medicine at the Western Australian Institute for Medical Research (WAIMR) has recently been completed. Further details of the review and an announcement of the results of research and developments on the project will shortly be made.

Dr Lalonde was part of the original team at the University of Western Australia that discovered and patented the HLS5 gene. Dr Lalonde was credited as the primary author on the major HLS5 project publication in the highly regarded international scientific journal, The Journal of Biological Chemistry.

Dr Lalonde has recently completed his MBBS training as a Medical Practitioner and was simultaneously enrolled in his PhD during his medical training. He was the first joint MBBS/PhD candidate at the University of Western Australia. Dr Lalonde's PhD project was on the cloning and characterization of HSL5.

Dr Lalonde has been appointed to the expanded research team under Professor Peter Klinken. Professor Klinken is the Director of WAIMR and the Centre for Medical Research at the University of Western Australia and manages over 160 staff at the Institute. He is a world- leading scientist whose research focuses on identifying genes which when mutated or inactivated, cause leukaemias and cancers.

The HLS5 project is being conducted with the University of Western Australia and the Western Australian Institute for Medical Research. The Institute combines the Royal Perth Hospital, Sir Charles Gairdner Hospital, Fremantle Hospital and the University of Western Australia.

Managing Director David Breeze said, "WAIMR and the Laboratory for Cancer Medicine is globally recognised for their expertise in cancer research and we are exceptionally pleased to be working with a research team led by a scientist such as Professor Peter Klinken and to have Dr Lalonde join the project team. We are extremely positive about the prospects of the current work being completed".

David Breeze,

Managing Director  
BioPharmica Limited

## **About - BioPharmica Ltd**

BioPharmica is commercialising a portfolio of Australian biomedical research discovered by Australian universities, medical institutes and hospitals targeting large global markets. The Company has several projects currently undergoing trials in Australian hospitals.

In conjunction with the University of Western Australia and the Western Australian Institute for Medical Research, the Company is commercialising a molecular marker for early and accurate cancer detection. The HLS5 genetic marker is currently undergoing validation trials at Royal Perth Hospital and targets billion-dollar markets.

In partnership with Cortical Dynamics Pty Ltd, the Company is commercialising the BAR Monitor, a device that measures a patient's brain electrical activity (EEG) to indicate the response to drugs administered during surgery. The BAR Monitor assists doctors to ensure patients do not wake up unexpectedly during an operation, and minimizes associated side effects from post-operative recall of surgical procedures. The BAR Monitor is currently undergoing trials at Royal Melbourne Hospital.

Together with the Royal Melbourne Institute of Technology University and Diagnostic Array Systems, the Company is commercialising faster and more effective methods of detecting infectious diseases using the genetic structure (DNA) of bacteria. Founders Dr Benjamin Fry and Dr Viraj Nawagamuwa are both world leaders in the genetic structure of bacteria.

In conjunction with Swinburne University of Technology and Dr Paul Stoddart, BioPharmica is commercialising the SERS Probe, a fibre optic probe to be used in biosensors for diagnostic testing and drug development. The probe enables the microscopic tip of an optical fibre to be used in biosensors to detect and monitor biological and chemical targets. Biosensor manufacturers have seen rapid growth with the 2003 worldwide market for biosensors at US \$ 7.3 billion.